NovaBridge Biosciences (FRA:0VY)

Germany flag Germany · Delayed Price · Currency is EUR
3.180
-0.160 (-4.79%)
Last updated: Jan 9, 2026, 8:02 AM CET
238.30%
Market Cap366.73M
Revenue (ttm)n/a
Net Income (ttm)-22.44M
Shares Outn/a
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume5
Open3.180
Previous Close3.340
Day's Range3.180 - 3.180
52-Week Range0.555 - 5.600
Betan/a
RSI45.24
Earnings DateApr 1, 2026

About NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 32
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0VY
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.